GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Fulvestrant

Company
Hoffmann-La Roche
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
97 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

97 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Fulvestrant and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02476786

    Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

    Not yet reported Washington University School of Medicine 50 participants Est. completion 2032-07-31 1 site Stand-alone
    Other conditions: Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
    View official trial listing →
  • Recruiting NCT NCT03424005

    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

    Not yet reported, Not yet reported Hoffmann-La Roche 1132 participants Est. completion 2030-09-30 53 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04263298

    Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

    Not yet reported Herui Yao 210 participants Est. completion 2030-05-01 13 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04606446

    Study of PF-07248144 in Advanced or Metastatic Solid Tumors

    Not yet reported Pfizer 320 participants Est. completion 2029-08-10 44 sites Stand-alone
    Other conditions: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT04646759

    Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 516 participants Est. completion 2030-12-14 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04923542

    SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

    Not yet reported, Not yet reported H. Lee Moffitt Cancer Center and Research Institute 31 participants Est. completion 2026-12 2 sites Stand-alone
    Other conditions: Brain Metastases, HR+ Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04985266

    A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

    Not yet reported Royal Marsden NHS Foundation Trust 1100 participants Est. completion 2030-09-01 49 sites Stand-alone
    Other conditions: ER+ Breast Cancer, HER2-negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05113368

    Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

    Not yet reported Sarah K. Lynam MD 31 participants Est. completion 2027-02 1 site Stand-alone
    Other conditions: Ovarian Cancer, Serous Ovarian Cancer
    View official trial listing →
  • Recruiting NCT NCT05216432

    First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    Not yet reported Relay Therapeutics, Inc. 930 participants Est. completion 2027-04-30 37 sites Stand-alone
    Other conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT05307705

    A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

    Not yet reported Eli Lilly and Company 260 participants Est. completion 2026-12 50 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05362760

    Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

    Not yet reported Prof. Wolfgang Janni 300 participants Est. completion 2029-04 54 sites Stand-alone
    Other conditions: Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05455619

    Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

    Not yet reported, Not yet reported SynDevRx, Inc. 52 participants Est. completion 2027-03 10 sites
    Other conditions: HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05467891

    Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

    Not yet reported Oana Danciu 200 participants Est. completion 2029-08-15 21 sites Stand-alone
    Other conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05472792

    Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

    Not yet reported UNC Lineberger Comprehensive Cancer Center 90 participants Est. completion 2032-04-15 1 site
    Other conditions: Breast Cancer, Quality of Life
    View official trial listing →
  • Recruiting NCT NCT05536128

    Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

    Not yet reported Seoul National University Hospital 64 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05564377

    Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    Not yet reported National Cancer Institute (NCI) 2900 participants Est. completion 2030-07-01 482 sites Stand-alone
    Other conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
    View official trial listing →
  • Recruiting NCT NCT05601440

    Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

    Not yet reported Canadian Cancer Trials Group 484 participants Est. completion 2028-06-30 10 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05608252

    VS-6766+Abema+Fulv in Met HR+/HER- BC

    Not yet reported, Not yet reported Adrienne G. Waks 63 participants Est. completion 2028-12-31 3 sites Stand-alone
    Other conditions: Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05646862

    A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

    Not yet reported Hoffmann-La Roche 420 participants Est. completion 2029-03-30 210 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05683418

    A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

    Not yet reported Totus Medicines 241 participants Est. completion 2027-12 18 sites Stand-alone
    Other conditions: HR+/HER2-negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05696626

    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    Not yet reported LeonaBio 600 participants Est. completion 2028-04 224 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05720260

    Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

    Not yet reported National Taiwan University Hospital 42 participants Est. completion 2027-01-31 1 site Stand-alone
    Other conditions: Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05735080

    Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    Not yet reported, Not yet reported Incyclix Bio 150 participants Est. completion 2027-09 18 sites Stand-alone
    Other conditions: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
    View official trial listing →
  • Recruiting NCT NCT05759546

    PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

    Not yet reported Fudan University 200 participants Est. completion 2027-06-01 1 site Stand-alone
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Recruiting NCT NCT05768139

    First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

    Not yet reported, Not yet reported Eli Lilly and Company 880 participants Est. completion 2030-07 65 sites Stand-alone
    Other conditions: Breast Cancer, Solid Tumors, Adult
    View official trial listing →
  • Recruiting NCT NCT05816655

    Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

    Not yet reported Korea University Guro Hospital 202 participants Est. completion 2029-06-30 2 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05860465

    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

    Not yet reported, Not yet reported Shanghai Pharmaceuticals Holding Co., Ltd 254 participants Est. completion 2026-12-30 22 sites Stand-alone
    Other conditions: Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05867251

    Study of AVZO-021 in Patients With Advanced Solid Tumors

    Not yet reported, Not yet reported Avenzo Therapeutics, Inc. 430 participants Est. completion 2030-01-31 13 sites Stand-alone
    Other conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05872347

    Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

    Not yet reported Shanghai Pharmaceuticals Holding Co., Ltd 52 participants Est. completion 2026-12-31 25 sites Stand-alone
    Other conditions: Breast Cancer Brain Metastases
    View official trial listing →
  • Recruiting NCT NCT05890287

    A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

    Not yet reported Tianjin Medical University Cancer Institute and Hospital 60 participants Est. completion 2026-10-01 1 site Stand-alone
    Other conditions: HR Positive HER2 Negative Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05933395

    Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

    Not yet reported Dartmouth-Hitchcock Medical Center 135 participants Est. completion 2031-10 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05949541

    Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer

    Not yet reported Fudan University 265 participants Est. completion 2028-01 1 site Stand-alone
    Other conditions: Breast Cancer, Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05983107

    Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

    Not yet reported Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102 participants Est. completion 2027-07-15 1 site Stand-alone
    Other conditions: HR+/HER2- Advanced Breast Cancer, Targeted Therapy
    View official trial listing →
  • Recruiting NCT NCT05985655

    Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

    Not yet reported, Not yet reported Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 230 participants Est. completion 2028-05 15 sites Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
    View official trial listing →
  • Recruiting NCT NCT06110793

    A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 56 participants Est. completion 2027-11 7 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06120283

    BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

    Not yet reported BeOne Medicines 433 participants Est. completion 2029-12 62 sites Stand-alone
    Other conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06135714

    Metastasis-directed Therapy for Oligometastases of Breast Cancer

    Not yet reported Tokyo Medical and Dental University 340 participants Est. completion 2032-10-31 1 site Stand-alone
    Other conditions: Breast Cancer, Oligometastasis, Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06145308

    Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

    Not yet reported Peking Union Medical College 39 participants Est. completion 2028-07-10 2 sites Stand-alone
    Other conditions: Salivary Gland Carcinoma, Precision Therapy
    View official trial listing →
  • Recruiting NCT NCT06176534

    Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

    Not yet reported Henan Cancer Hospital 240 participants Est. completion 2026-12-20 1 site
    Other conditions: Advanced Breast Cancer, Treatment, HR Low/HER2 Negative
    View official trial listing →
  • Recruiting NCT NCT06179303

    Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

    Not yet reported University of Washington 60 participants Est. completion 2028-06-01 2 sites Stand-alone
    Other conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06202261

    A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

    Not yet reported, Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 154 participants Est. completion 2027-10 2 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies
    View official trial listing →
  • Recruiting NCT NCT06208410

    A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

    Not yet reported, Not yet reported Risen (Suzhou) Pharma Tech Co., Ltd. 306 participants Est. completion 2027-02-26 1 site Stand-alone
    Other conditions: Advanced Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT06341894

    Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 1163 participants Est. completion 2029-06 1 site Stand-alone
    Other conditions: Early Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06377852

    The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    Not yet reported American Society of Clinical Oncology 500 participants Est. completion 2028-09-01 73 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06380751

    Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

    Not yet reported AstraZeneca 788 participants Est. completion 2031-12-30 306 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06409390

    Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 15 participants Est. completion 2027-04 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06431243

    A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors

    Not yet reported, Not yet reported Chengdu Zenitar Biomedical Technology Co., Ltd 132 participants Est. completion 2026-11-01 2 sites Stand-alone
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT06447623

    Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

    Not yet reported Fudan University 184 participants Est. completion 2029-02-01 1 site Stand-alone
    Other conditions: Advanced Breast Cancer, HR+/HER2- Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06515470

    Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

    Not yet reported Biotheryx, Inc. 82 participants Est. completion 2027-12-31 6 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06548919

    Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer

    SciClone Pharmaceuticals 450 participants Est. completion 2027-12-31 1 site
    Other conditions: ESR1 Gene Mutation, Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06555068

    A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

    Not yet reported, Not yet reported Jiangsu HengRui Medicine Co., Ltd. 528 participants Est. completion 2028-08 1 site Stand-alone
    Other conditions: Advanced Unresectable or Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06607757

    Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

    Not yet reported GBG Forschungs GmbH 120 participants Est. completion 2026-08-31 25 sites Stand-alone
    Other conditions: CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
    View official trial listing →
  • Recruiting NCT NCT06625775

    Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    Not yet reported TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 392 participants Est. completion 2028-11 44 sites Stand-alone
    Other conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06663072

    Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

    Not yet reported University of Chicago 25 participants Est. completion 2026-11 1 site Stand-alone
    Other conditions: Metastatic Pancreatic Neuroendocrine Tumor
    View official trial listing →
  • Recruiting NCT NCT06726148

    Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

    Not yet reported, Not yet reported Novartis Pharmaceuticals 280 participants Est. completion 2028-09-25 33 sites Stand-alone
    Other conditions: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT06734533

    Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

    Hunan Cancer Hospital 80 participants Est. completion 2025-12-30 1 site
    Other conditions: HR+ Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06736704

    SNV4818 in Participants With Advanced Solid Tumors

    Not yet reported, Not yet reported Pikavation Therapeutics, Inc. 320 participants Est. completion 2027-06 12 sites Stand-alone
    Other conditions: Advanced Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT06756932

    BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

    Not yet reported BeOne Medicines 120 participants Est. completion 2027-07-30 14 sites Stand-alone
    Other conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06757634

    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    Not yet reported Celcuity Inc 1180 participants Est. completion 2033-07-30 203 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06784193

    Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    Not yet reported Olema Pharmaceuticals, Inc. 180 participants Est. completion 2027-08-30 8 sites Stand-alone
    Other conditions: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant
    View official trial listing →
  • Recruiting NCT NCT06837792

    Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

    Not yet reported Yonsei University 141 participants Est. completion 2026-10-01 1 site
    Other conditions: Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)
    View official trial listing →
  • Recruiting NCT NCT06843967

    A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 54 participants Est. completion 2028-08-19 7 sites Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Recruiting NCT NCT06950086

    Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors

    Not yet reported, Not yet reported TYK Medicines, Inc 180 participants Est. completion 2026-11 2 sites Stand-alone
    Other conditions: HR-positive, HER2-negative Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06954961

    A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

    Not yet reported InventisBio Co., Ltd 640 participants Est. completion 2028-12-31 2 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06979596

    A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

    Not yet reported Merck Sharp & Dohme LLC 250 participants Est. completion 2027-11-04 59 sites Stand-alone
    Other conditions: Malignant Neoplasm
    View official trial listing →
  • Recruiting NCT NCT06982521

    Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    Not yet reported Relay Therapeutics, Inc. 540 participants Est. completion 2031-12-31 231 sites Stand-alone
    Other conditions: PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06997029

    A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    Not yet reported Bristol-Myers Squibb 234 participants Est. completion 2028-12-14 21 sites Stand-alone
    Other conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
    View official trial listing →
  • Recruiting NCT NCT06998108

    Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

    Not yet reported BeBetter Med Inc 330 participants Est. completion 2026-06-30 1 site
    Other conditions: HR+/HER2- Locally Advanced, Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06998407

    ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

    Not yet reported, Not yet reported Avenzo Therapeutics, Inc. 380 participants Est. completion 2030-08 16 sites Stand-alone
    Other conditions: HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07029399

    A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

    Not yet reported NiKang Therapeutics, Inc. 361 participants Est. completion 2027-12-31 18 sites Stand-alone
    Other conditions: HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07037199

    Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 45 participants Est. completion 2030-06-30 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07114601

    A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    Not yet reported Eli Lilly and Company 421 participants Est. completion 2035-04 33 sites Stand-alone
    Other conditions: Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms
    View official trial listing →
  • Recruiting NCT NCT07117630

    An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

    Not yet reported Fudan University 60 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07174336

    A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    Not yet reported Eli Lilly and Company 800 participants Est. completion 2033-05 360 sites Stand-alone
    Other conditions: Breast Neoplasms, Neoplasm Metastasis
    View official trial listing →
  • Recruiting NCT NCT07180160

    Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

    Not yet reported Wenjin Yin 123 participants Est. completion 2028-03 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07207070

    A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

    Not yet reported Risen (Suzhou) Pharma Tech Co., Ltd. 312 participants Est. completion 2030-05-31 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07226349

    A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

    Not yet reported BeOne Medicines 105 participants Est. completion 2028-11-01 22 sites Stand-alone
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT07227233

    Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

    Not yet reported University of California, San Diego 105 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07235176

    Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients

    Not yet reported, Not yet reported Qilu Pharmaceutical Co., Ltd. 300 participants Est. completion 2031-12-30 1 site Stand-alone
    Other conditions: Advanced ER+/HER2- Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07287917

    Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

    Not yet reported, Not yet reported Aminex Therapeutics, Inc. 92 participants Est. completion 2028-12-29 20 sites Stand-alone
    Other conditions: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07288359

    Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

    Not yet reported, Not yet reported Novartis Pharmaceuticals 205 participants Est. completion 2031-05-09 15 sites Stand-alone
    Other conditions: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
    View official trial listing →
  • Recruiting NCT NCT07318805

    A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

    Not yet reported Pfizer 260 participants Est. completion 2030-04-14 13 sites Stand-alone
    Other conditions: Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07330544

    A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

    Not yet reported Zhejiang Cancer Hospital 118 participants Est. completion 2028-11-26 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07347600

    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

    Hoffmann-La Roche 500 participants Est. completion 2029-12-31 30 sites
    Other conditions: Locally Advanced Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07354022

    A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

    Not yet reported Shandong Suncadia Medicine Co., Ltd. 912 participants Est. completion 2031-12 1 site
    Other conditions: Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07368998

    To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

    Not yet reported Hoffmann-La Roche 80 participants Est. completion 2031-10-31 34 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07389733

    A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

    Not yet reported, Not yet reported Shandong Suncadia Medicine Co., Ltd. 180 participants Est. completion 2028-12 2 sites Stand-alone
    Other conditions: Advanced Unresectable or Metastatic Breast Cancer of Adults
    View official trial listing →
  • Recruiting NCT NCT07426822

    Rash & Diarrhea Prophylaxis With Capivasertib

    Not yet reported Maryam Lustberg 108 participants Est. completion 2029-04 1 site Stand-alone
    Other conditions: Metastatic HR+/HER2- Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07498478

    Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

    Not yet reported TransThera Sciences (Nanjing), Inc. 94 participants Est. completion 2027-12-31 13 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07558733

    Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

    Not yet reported, Not yet reported Faeth Therapeutics 32 participants Est. completion 2033-05 7 sites Stand-alone
    Other conditions: HR+ HER2- Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07581834

    Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

    Not yet reported Fujian Cancer Hospital 2000 participants Est. completion 2032-06-30 2 sites Stand-alone
    Other conditions: Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases, CDK4/6 Inhibitor, HR+/HER2- Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07604272

    Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males

    Not yet reported Northwestern University 30 participants Est. completion 2028-07 1 site Stand-alone
    Other conditions: Inguinal Hernia Unilateral, Inguinal Hernia Bilateral, Inguinal Hernia Without Obstruction or Gangrene, Inguinal Hernia, Without Mention of Obstruction or Gangrene
    View official trial listing →
  • Recruiting NCT NCT07604571

    Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

    Not yet reported Novartis Pharmaceuticals 194 participants Est. completion 2032-06-08 6 sites Stand-alone
    Other conditions: Advanced HR+/HER2- Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07610720

    Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

    Not yet reported Sun Yat-sen University 57 participants Est. completion 2029-11-01 1 site Stand-alone
    Other conditions: Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07666555

    A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.

    Not yet reported Fudan University 98 participants Est. completion 2029-12-30 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07708194

    Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure

    Not yet reported, Not yet reported Tianjin Medical University Cancer Institute and Hospital 94 participants Est. completion 2027-02 1 site Stand-alone
    Other conditions: Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07810088

    Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer

    Not yet reported Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 40 participants Est. completion 2028-12-01 1 site Stand-alone
    Other conditions: HR+ / HER2- Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT00006903

    Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

    Not yet reported Gynecologic Oncology Group 67 participants Stand-alone
    Other conditions: Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7
    View official trial listing →
  • Completed NCT NCT00012025

    ICI 182780 in Treating Women With Metastatic Breast Cancer

    Not yet reported Alliance for Clinical Trials in Oncology 80 participants Est. completion 2008-08 25 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00046371

    Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients

    Not yet reported Oncothyreon Canada Inc. Est. completion 2005-08 17 sites
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT00057941

    Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

    Not yet reported National Cancer Institute (NCI) 148 participants Est. completion 2012-06 1 site Stand-alone
    Other conditions: Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Completed NCT NCT00065325

    The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

    Not yet reported AstraZeneca 694 participants Est. completion 2014-09 117 sites Stand-alone
    Other conditions: Locally Advanced Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00075764

    S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

    Not yet reported SWOG Cancer Research Network 695 participants Est. completion 2018-10-01 426 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00082810

    Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

    Not yet reported National Cancer Institute (NCI) 33 participants Est. completion 2008-09 1 site Stand-alone
    Other conditions: Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT00099437

    Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

    Not yet reported AstraZeneca 736 participants Est. completion 2026-12-31 106 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00100854

    Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    Not yet reported Translational Oncology Research International 108 participants Est. completion 2018-09-05 1 site Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT00126464

    Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

    Not yet reported Cedars-Sinai Medical Center 100 participants 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00146601

    Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

    Not yet reported Dana-Farber Cancer Institute 35 participants Est. completion 2007-07 4 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00183963

    A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

    Not yet reported University of Southern California 4 participants Est. completion 2008-06 1 site
    Other conditions: Breast Carcinoma
    View official trial listing →
  • Completed NCT NCT00201864

    Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer

    Not yet reported Ohio State University Comprehensive Cancer Center 40 participants Est. completion 2014-02 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00206414

    Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

    Not yet reported Baylor Breast Care Center 15 participants Est. completion 2006-09 1 site
    Other conditions: BREAST CANCER
    View official trial listing →
  • Terminated NCT NCT00217464

    Fulvestrant in Treating Patients With Recurrent Prostate Cancer

    Not yet reported Roswell Park Cancer Institute 17 participants Est. completion 2010-03 1 site Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00234403

    A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

    Not yet reported AstraZeneca 60 participants Est. completion 2007-10 7 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00241449

    A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

    Not yet reported AstraZeneca 51 participants Est. completion 2012-01 139 sites Stand-alone
    Other conditions: Breast Cancer, Metastasis
    View official trial listing →
  • Terminated NCT NCT00241462

    Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients

    AstraZeneca 150 participants Est. completion 2009-12 43 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00244998

    Fulvestrant in Treating Patients With Advanced Prostate Cancer

    Not yet reported Roswell Park Cancer Institute 20 participants Est. completion 2012-06 1 site
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00253422

    Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors

    Not yet reported Institute of Cancer Research, United Kingdom 698 participants Est. completion 2022-11-28 2 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00256698

    Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

    Not yet reported AstraZeneca 514 participants Est. completion 2012-02 85 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00259090

    Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

    Not yet reported AstraZeneca 120 participants Est. completion 2008-10 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00274469

    A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer

    Not yet reported AstraZeneca 205 participants Est. completion 2017-01-13 41 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00278915

    Faslodex in McCune-Albright Syndrome

    Not yet reported AstraZeneca 30 participants Est. completion 2023-07-20 16 sites Stand-alone
    Other conditions: Puberty, Precocious, McCune-Albright Syndrome
    View official trial listing →
  • Completed NCT NCT00305448

    A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg

    Not yet reported AstraZeneca 143 participants Est. completion 2012-02 35 sites Stand-alone
    Other conditions: Advanced Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00313170

    A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

    Not yet reported AstraZeneca 144 participants Est. completion 2019-03-13 34 sites Stand-alone
    Other conditions: Advanced Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00327769

    Faslodex Advanced Breast Cancer Local Chinese Study

    Not yet reported AstraZeneca 234 participants Est. completion 2007-09 12 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT00328120

    Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

    Not yet reported AstraZeneca 20 participants Est. completion 2010-06 5 sites
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT00334295

    Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

    Not yet reported AstraZeneca 35 participants Est. completion 2011-01 9 sites
    Other conditions: Endometrial Carcinoma
    View official trial listing →
  • Completed NCT NCT00357110

    Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer

    Not yet reported AstraZeneca 13 participants Est. completion 2008-10 25 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00372996

    Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

    Not yet reported Pfizer 219 participants Est. completion 2014-06 62 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT00390455

    Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

    Not yet reported National Cancer Institute (NCI) 295 participants Est. completion 2014-07-02 368 sites Stand-alone
    Other conditions: Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT00405938

    Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer

    Not yet reported SCRI Development Innovations, LLC 79 participants Est. completion 2011-06 11 sites Stand-alone
    Other conditions: Breast Cancer, Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT00417430

    Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies

    Not yet reported The Center for Rheumatic Disease, Allergy, & Immunology 20 participants Est. completion 2006-12 1 site
    Other conditions: Systemic Lupus Erythematosus
    View official trial listing →
  • Completed NCT NCT00451555

    Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer

    Not yet reported Eli Lilly and Company 156 participants Est. completion 2018-10-18 21 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00454805

    AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

    Not yet reported AstraZeneca 75 participants Est. completion 2016-04 16 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT00476645

    Fulvestrant in Hormone Refractory Prostate Cancer

    Not yet reported Stanford University 10 participants Est. completion 2009-12 1 site Stand-alone
    Other conditions: Prostatic Neoplasms, Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00534417

    Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

    Not yet reported Accelerated Community Oncology Research Network 41 participants Est. completion 2011-09 10 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00543127

    Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

    Not yet reported Spanish Breast Cancer Research Group 870 participants Est. completion 2016-07 53 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00545077

    Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

    Not yet reported Spanish Breast Cancer Research Group 380 participants Est. completion 2014-07-24 70 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00570258

    Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

    Not yet reported University of Arkansas 27 participants Est. completion 2017-12 6 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00570323

    Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer

    Not yet reported Mothaffar Rimawi 72 participants Est. completion 2018-12-05 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00570921

    Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

    Not yet reported Mara Chambers 33 participants Est. completion 2015-01 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT00585507

    Efficacy and Safety of 500mg of Fulvestrant

    Not yet reported Beth Israel Deaconess Medical Center 40 participants Est. completion 2027-03-15 5 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00617188

    Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer

    Not yet reported Masonic Cancer Center, University of Minnesota 26 participants Est. completion 2008-07 1 site Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT00626106

    QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

    Not yet reported NantCell, Inc. 156 participants Est. completion 2011-09-23 60 sites
    Other conditions: Breast Cancer, Breast Tumors, Metastatic Cancer
    View official trial listing →
  • Completed NCT NCT00629616

    Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer

    Not yet reported UNICANCER 116 participants Est. completion 2018-04 6 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00643513

    Quality Of Life While Receiving Faslodex

    AstraZeneca 120 participants Est. completion 2009-01 24 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00660803

    Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer

    AstraZeneca 200 participants Est. completion 2009-04 4 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00681369

    Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

    AstraZeneca 217 participants Est. completion 2007-06
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00722072

    Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

    Not yet reported OHSU Knight Cancer Institute 12 participants Est. completion 2012-07 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00728949

    A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

    Not yet reported Eli Lilly and Company 93 participants Est. completion 2015-02 9 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00735215

    Faslodex Registry: Fulvestrant in Current Clinical Practice

    AstraZeneca 200 participants Est. completion 2009-12 12 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00752986

    ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial

    Not yet reported Genzyme, a Sanofi Company 39 participants Est. completion 2013-09 11 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00774878

    Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer

    Not yet reported Sanofi 18 participants Est. completion 2010-11 3 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT00811369

    Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer

    Not yet reported Ontario Clinical Oncology Group (OCOG) 126 participants Est. completion 2013-08 13 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00816582

    PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer

    Not yet reported British Columbia Cancer Agency 17 participants Est. completion 2018-07 4 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00860561

    Faslodex Post Marketing Surveillance

    AstraZeneca 42 participants Est. completion 2013-10 7 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00871858

    Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer

    Not yet reported Institut Bergonié 120 participants Est. completion 2018-07-02 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00878930

    Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer

    AstraZeneca 500 participants Est. completion 2010-12 16 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00921115

    Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

    Not yet reported University of Kansas Medical Center 42 participants Est. completion 2023-03-20 1 site Stand-alone
    Other conditions: Invasive Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT00927511

    A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)

    Not yet reported Regina Elena Cancer Institute 104 participants Est. completion 2012-04 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00944918

    Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

    Not yet reported AstraZeneca 25 participants Est. completion 2011-06 2 sites Stand-alone
    Other conditions: Progression-free Survival
    View official trial listing →
  • Withdrawn NCT NCT01004419

    Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer

    Not yet reported University of Wisconsin, Madison Est. completion 2011-05 Stand-alone
    Other conditions: Carcinoma, Non Small Cell Lung
    View official trial listing →
  • Completed NCT NCT01142401

    Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

    Not yet reported National Cancer Institute (NCI) 118 participants Est. completion 2021-01-08 21 sites Stand-alone
    Other conditions: Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT01160718

    Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

    Not yet reported Swiss Cancer Institute 46 participants Est. completion 2016-09 17 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01171417

    A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer

    AstraZeneca 570 participants Est. completion 2013-11 92 sites
    Other conditions: Postmenopause, Breast Cancer
    View official trial listing →
  • Completed NCT NCT01202591

    Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients

    Not yet reported, Not yet reported AstraZeneca 127 participants Est. completion 2014-10 21 sites Stand-alone
    Other conditions: FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01233947

    Study of AFP464 +/- Faslodex in ER + Breast Cancer

    Not yet reported Tigris Pharmaceuticals 7 participants Est. completion 2012-08 1 site
    Other conditions: Breast Neoplasm
    View official trial listing →
  • Status unknown NCT NCT01266213

    Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women

    Not yet reported Samsung Medical Center 147 participants Est. completion 2019-12 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer, Estrogen Receptor Positive Tumor, Breast Cancer Nos Premenopausal
    View official trial listing →
  • Terminated NCT NCT01296555

    A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

    Not yet reported Genentech, Inc. 674 participants Est. completion 2021-06-25 31 sites Stand-alone
    Other conditions: Solid Cancers, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01300351

    Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women

    Not yet reported AstraZeneca 249 participants Est. completion 2014-03 15 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01339442

    BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer

    Not yet reported Washington University School of Medicine 31 participants Est. completion 2016-12-28 1 site Stand-alone
    Other conditions: Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Completed NCT NCT01344031

    MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

    Not yet reported National Cancer Institute (NCI) 31 participants 1 site Stand-alone
    Other conditions: Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT01377324

    Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites

    Not yet reported University Medical Center Groningen 16 participants Est. completion 2013-08 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT01394016

    A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

    Not yet reported Eli Lilly and Company 225 participants Est. completion 2022-04-12 3 sites Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Terminated NCT NCT01425294

    Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

    AstraZeneca 231 participants Est. completion 2016-01-30 23 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01437566

    Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy

    Not yet reported Genentech, Inc. 318 participants Est. completion 2016-04 130 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01441947

    Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

    Not yet reported Massachusetts General Hospital 68 participants Est. completion 2019-08-09 4 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01501266

    Faslodex Specific Clinical Experience Investigation

    AstraZeneca 660 participants Est. completion 2015-01 43 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01509625

    Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)

    Isabel Blancas 272 participants Est. completion 2014-03 7 sites
    Other conditions: Malignant Neoplasm of Breast Stage IV
    View official trial listing →
  • Terminated NCT NCT01528345

    Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

    Not yet reported Novartis Pharmaceuticals 97 participants Est. completion 2015-04 67 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT01556191

    Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR

    Not yet reported Intergroupe Francophone de Cancerologie Thoracique 379 participants Est. completion 2020-06-17 61 sites Stand-alone
    Other conditions: Stage IV Lung Cancer
    View official trial listing →
  • Completed NCT NCT01560416

    Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

    Not yet reported Dana-Farber Cancer Institute 50 participants Est. completion 2016-06-26 5 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01597388

    AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

    Not yet reported AstraZeneca 99 participants Est. completion 2026-01-13 5 sites Stand-alone
    Other conditions: Advanced Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT01610284

    Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

    Not yet reported Novartis Pharmaceuticals 1147 participants Est. completion 2019-04-19 268 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01655225

    A Study of LY3023414 in Participants With Advanced Cancer

    Not yet reported Eli Lilly and Company 156 participants Est. completion 2022-02-02 8 sites Stand-alone
    Other conditions: Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT01670877

    Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

    Not yet reported Washington University School of Medicine 56 participants Est. completion 2021-03-11 17 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT01701050

    Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index

    Janssen Diagnostics, LLC 121 participants Est. completion 2016-11-10 20 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT01714128

    FES-PET for Patients Treated on NCI Protocol 8762

    Not yet reported Washington University School of Medicine Est. completion 2015-12 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01797120

    Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

    Not yet reported PrECOG, LLC. 131 participants Est. completion 2017-09-12 25 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01823835

    A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

    Not yet reported, Not yet reported Genentech, Inc. 152 participants Est. completion 2020-03-13 14 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01942135

    Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

    Not yet reported Pfizer 521 participants Est. completion 2022-09-28 247 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01953926

    Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

    Not yet reported Puma Biotechnology, Inc. 582 participants Est. completion 2023-01-02 60 sites Stand-alone
    Other conditions: Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
    View official trial listing →
  • Active, not recruiting NCT NCT01992952

    Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

    Not yet reported, Not yet reported Velindre NHS Trust 149 participants Est. completion 2025-12-31 21 sites Stand-alone
    Other conditions: Estrogen Receptor Positive Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02000193

    Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer

    Not yet reported Sun Yat-sen University 58 participants Est. completion 2018-12 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02000596

    1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

    Not yet reported University of Maryland, Baltimore 2 participants Est. completion 2016-01 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02049957

    Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

    Not yet reported Calithera Biosciences, Inc 118 participants Est. completion 2018-06-29 40 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02057133

    A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

    Not yet reported Eli Lilly and Company 198 participants Est. completion 2026-12 13 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Status unknown NCT NCT02072512

    The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer

    Not yet reported Hospital Affiliated to Military Medical Science, Beijing 180 participants Est. completion 2016-12 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02107703

    A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

    Not yet reported Eli Lilly and Company 669 participants Est. completion 2027-12 146 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Withdrawn NCT NCT02115594

    Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer

    Not yet reported Syndax Pharmaceuticals Est. completion 2016-06 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02116803

    An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

    Not yet reported, Not yet reported Novartis Pharmaceuticals 12 participants Est. completion 2016-11-28 9 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT02137083

    A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer

    Not yet reported Fudan University 22 participants Est. completion 2017-07 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT02140437

    Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC

    Not yet reported Fudan University Est. completion 2016-06 Stand-alone
    Other conditions: Carcinoma Breast Stage IV
    View official trial listing →
  • Completed NCT NCT02206984

    Endocrine Response in Women With Invasive Lobular Breast Cancer

    Not yet reported Priscilla McAuliffe 201 participants Est. completion 2024-07-19 12 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02219789

    Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

    Not yet reported Mayo Clinic 10 participants Est. completion 2018-10-01 1 site Stand-alone
    Other conditions: Estrogen Receptor Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02238509

    Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies

    Not yet reported Consorzio Oncotech 154 participants Est. completion 2017-10 36 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02260661

    Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

    Not yet reported AstraZeneca 20 participants Est. completion 2016-07 9 sites Stand-alone
    Other conditions: Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -, Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
    View official trial listing →
  • Terminated NCT NCT02269670

    Phase II Study of Everolimus Beyond Progression

    Not yet reported Emory University 3 participants Est. completion 2021-01-25 3 sites Stand-alone
    Other conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Completed NCT NCT02291913

    Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

    Not yet reported SCRI Development Innovations, LLC 48 participants Est. completion 2019-01-31 8 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02333370

    A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

    Not yet reported Novartis Pharmaceuticals 88 participants Est. completion 2022-09-29 15 sites Stand-alone
    Other conditions: Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02340221

    A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

    Not yet reported Hoffmann-La Roche 631 participants Est. completion 2021-06-29 157 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02344472

    Detect V / CHEVENDO (Chemo vs. Endo)

    Not yet reported Prof. Wolfgang Janni 271 participants Est. completion 2025-01-31 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02345772

    Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

    Not yet reported, Not yet reported Western Regional Medical Center 4 participants Est. completion 2015-11 1 site Stand-alone
    Other conditions: HER2-positive Breast Cancer, ER-positive Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02374099

    Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

    Not yet reported Celgene 97 participants Est. completion 2017-11-21 35 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Status unknown NCT NCT02383030

    Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients

    Not yet reported Consorzio Oncotech 156 participants Est. completion 2017-12 20 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02384239

    A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

    Not yet reported University of California, San Francisco 70 participants Est. completion 2021-01-31 9 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, Hormone Receptor Positive
    View official trial listing →
  • Completed NCT NCT02389842

    PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib

    Not yet reported Royal Marsden NHS Foundation Trust 79 participants Est. completion 2021-05-26 2 sites
    Other conditions: Advanced Solid Tumours, Breast Cancer
    View official trial listing →
  • Completed NCT NCT02392611

    Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

    Not yet reported Gilead Sciences 33 participants Est. completion 2017-10-11 4 sites Stand-alone
    Other conditions: Solid Tumors and Lymphomas
    View official trial listing →
  • Status unknown NCT NCT02394496

    Overcoming Endocrine Resistance in Metastatic Breast Cancer

    Not yet reported Consorzio Oncotech 396 participants Est. completion 2017-01 69 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02404051

    Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

    Not yet reported Consorzio Oncotech 745 participants Est. completion 2019-01 41 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Locally Advanced Malignant Neoplasm
    View official trial listing →
  • Completed NCT NCT02437318

    Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

    Not yet reported Novartis Pharmaceuticals 572 participants Est. completion 2023-06-09 197 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02448420

    Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

    Not yet reported SOLTI Breast Cancer Research Group 73 participants Est. completion 2023-11-30 35 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02530411

    Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer

    Not yet reported Velindre NHS Trust 160 participants Est. completion 2020-12 5 sites Stand-alone
    Other conditions: Neoplasms
    View official trial listing →
  • Completed NCT NCT02530424

    "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "

    Not yet reported Fondazione Michelangelo 102 participants Est. completion 2019-11 7 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT02536742

    Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

    Not yet reported ETOP IBCSG Partners Foundation 124 participants Est. completion 2022-12-22 19 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02540330

    A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant

    Not yet reported Atossa Therapeutics, Inc. 3 participants Est. completion 2020-08-13 3 sites Stand-alone
    Other conditions: Female Breast Carcinoma, Female Ductal Carcinoma In Situ
    View official trial listing →
  • Completed NCT NCT02549430

    To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy

    Not yet reported Fondazione Sandro Pitigliani 115 participants Est. completion 2017-02-09 6 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02569801

    A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy

    Not yet reported Genentech, Inc. 71 participants Est. completion 2020-02-28 44 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02599714

    Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer

    Not yet reported AstraZeneca 54 participants Est. completion 2023-11-23 7 sites Stand-alone
    Other conditions: Advanced and Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02626507

    Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

    Not yet reported Hoffman Oncology 18 participants Est. completion 2022-03-15 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02630693

    Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

    Not yet reported Canadian Cancer Trials Group 180 participants Est. completion 2023-11-29 22 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02640755

    Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase

    Not yet reported AstraZeneca 4 participants Est. completion 2017-07-06 1 site Stand-alone
    Other conditions: Solid Malignancies
    View official trial listing →
  • Status unknown NCT NCT02646735

    Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients

    Not yet reported Chinese Academy of Medical Sciences 148 participants Est. completion 2020-12 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02675231

    A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

    Not yet reported Eli Lilly and Company 237 participants Est. completion 2023-11-09 93 sites Stand-alone
    Other conditions: Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02690480

    Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer

    Not yet reported Spanish Breast Cancer Research Group 189 participants Est. completion 2023-12 32 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT02692755

    Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

    Not yet reported, Not yet reported Georgetown University 35 participants Est. completion 2021-03-23 6 sites Stand-alone
    Other conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02734615

    Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

    Not yet reported Novartis Pharmaceuticals 199 participants Est. completion 2021-09-13 10 sites
    Other conditions: Advanced or Metastatic ER+ Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02738866

    Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 60 participants Est. completion 2026-12 5 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02753686

    Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

    Novartis Pharmaceuticals 440 participants Est. completion 2022-12-01 25 sites
    Other conditions: HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT02760030

    Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

    Not yet reported Ohio State University Comprehensive Cancer Center 14 participants Est. completion 2025-08-31 3 sites Stand-alone
    Other conditions: Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02761694

    Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)

    Not yet reported ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 78 participants Est. completion 2021-03-10 6 sites Stand-alone
    Other conditions: Cancer, Solid Tumors
    View official trial listing →
  • Active, not recruiting NCT NCT02763566

    A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

    Not yet reported Eli Lilly and Company 463 participants Est. completion 2028-03 45 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02792465

    A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors

    Not yet reported University Health Network, Toronto 52 participants Est. completion 2025-06-12 3 sites Stand-alone
    Other conditions: Advanced Solid Cancers, Breast Cancer
    View official trial listing →
  • Completed NCT NCT02795039

    Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects

    Not yet reported Fresenius Kabi 266 participants Est. completion 2017-03-03 3 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02866149

    Analysis of Circulating Tumor Markers in the Blood (ALCINA)

    Not yet reported Institut Curie 682 participants Est. completion 2024-09 5 sites
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT02894398

    Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

    Not yet reported iOMEDICO AG 388 participants Est. completion 2023-02-15 70 sites Stand-alone
    Other conditions: Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    View official trial listing →
  • Status unknown NCT NCT02909361

    Fulvestrant 500mg in Patients With Advanced Breast Cancer

    Fudan University 500 participants Est. completion 2022-10 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02911844

    Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension

    Not yet reported University of Pennsylvania 5 participants Est. completion 2018-12-05 1 site
    Other conditions: Pulmonary Arterial Hypertension
    View official trial listing →
  • Active, not recruiting NCT NCT02947685

    Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

    Not yet reported Alliance Foundation Trials, LLC. 518 participants Est. completion 2026-07-31 106 sites Stand-alone
    Other conditions: HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
    View official trial listing →
  • Completed NCT NCT02953860

    Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer

    Not yet reported University of Colorado, Denver 32 participants Est. completion 2020-04-10 3 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02955394

    Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

    Not yet reported University of Colorado, Denver 61 participants Est. completion 2027-02 3 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02958852

    A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer

    Not yet reported Lund University Hospital 126 participants Est. completion 2025-01-15 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02964507

    Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

    Not yet reported GlaxoSmithKline 124 participants Est. completion 2021-07-19 38 sites Stand-alone
    Other conditions: Neoplasms
    View official trial listing →
  • Completed NCT NCT02970682

    SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer

    Not yet reported Evgen Pharma 60 participants Est. completion 2019-03 10 sites Stand-alone
    Other conditions: Breast Neoplasm
    View official trial listing →
  • Status unknown NCT NCT02983071

    G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

    Not yet reported, Not yet reported G1 Therapeutics, Inc. 102 participants Est. completion 2023-10 8 sites Stand-alone
    Other conditions: Carcinoma, Ductal, Breast, Breast Cancer, Breast Neoplasm
    View official trial listing →
  • Terminated NCT NCT02983604

    GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

    Not yet reported, Not yet reported Gilead Sciences 14 participants Est. completion 2018-07-19 6 sites Stand-alone
    Other conditions: Advanced Estrogen Receptor Positive HER2- Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03006172

    To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

    Not yet reported Genentech, Inc. 200 participants Est. completion 2026-12-31 12 sites Stand-alone
    Other conditions: Breast Cancer, Solid Tumor
    View official trial listing →
  • Completed NCT NCT03007979

    Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

    Not yet reported Washington University School of Medicine 55 participants Est. completion 2023-03-31 2 sites Stand-alone
    Other conditions: Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
    View official trial listing →
  • Status unknown NCT NCT03024580

    A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer

    Not yet reported Instituto Nacional de Cancer, Brazil 20 participants Est. completion 2020-09 1 site
    Other conditions: Breast Neoplasm
    View official trial listing →
  • Completed NCT NCT03079011

    PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

    Not yet reported UNICANCER 1017 participants Est. completion 2025-09-22 82 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT03099174

    This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

    Not yet reported Boehringer Ingelheim 133 participants Est. completion 2024-05-16 30 sites Stand-alone
    Other conditions: Neoplasms, Breast Neoplasms
    View official trial listing →
  • Terminated NCT NCT03134638

    A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

    Not yet reported Syros Pharmaceuticals 107 participants Est. completion 2020-06-24 20 sites Stand-alone
    Other conditions: Advanced Solid Tumors, Ovarian Cancer, Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03147287

    Palbociclib After CDK and Endocrine Therapy (PACE)

    Not yet reported Dana-Farber Cancer Institute 220 participants Est. completion 2026-12-30 22 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT03169738

    QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

    Not yet reported, Not yet reported ImmunityBio, Inc. Est. completion 2021-12-28 Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Withdrawn NCT NCT03169764

    QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

    Not yet reported, Not yet reported ImmunityBio, Inc. Est. completion 2021-12-28 Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT03169777

    QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

    Not yet reported, Not yet reported ImmunityBio, Inc. Est. completion 2021-12-28 Stand-alone
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT03179904

    TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

    Not yet reported Mayo Clinic 17 participants Est. completion 2026-03-13 3 sites Stand-alone
    Other conditions: Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03182634

    The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial

    Not yet reported Institute of Cancer Research, United Kingdom 1150 participants Est. completion 2023-11 19 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT03184090

    Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC

    Not yet reported MedSIR 33 participants Est. completion 2020-10-27 15 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03192293

    Metformin and Simvastatin in Addition to Fulvestrant

    Not yet reported National University Hospital, Singapore 28 participants Est. completion 2019-01-20 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT03197571

    QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

    Not yet reported, Not yet reported ImmunityBio, Inc. Est. completion 2021-12-28 Stand-alone
    Other conditions: Urothelial Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT03197584

    QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

    Not yet reported, Not yet reported ImmunityBio, Inc. Est. completion 2021-12-28 Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Status unknown NCT NCT03202862

    The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer

    Not yet reported Fudan University 50 participants Est. completion 2019-08-01 Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Terminated NCT NCT03220178

    Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

    Not yet reported Palleos Healthcare GmbH 532 participants Est. completion 2021-12-07 1 site Stand-alone
    Other conditions: Breast Neoplasm
    View official trial listing →
  • Completed NCT NCT03227328

    CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

    Not yet reported Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 52 participants Est. completion 2022-07-01 20 sites Stand-alone
    Other conditions: Hormone Receptor Positive Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT03236974

    Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

    Not yet reported AstraZeneca 49 participants Est. completion 2019-02-12 12 sites
    Other conditions: Postmenopausal Women With ER+ HER2- Primary Breast Cancer
    View official trial listing →
  • Completed NCT NCT03238196

    Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

    Not yet reported Vanderbilt-Ingram Cancer Center 35 participants Est. completion 2024-03-20 6 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03241810

    Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

    Not yet reported Elevation Oncology 22 participants Est. completion 2018-11-30 59 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03289039

    Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

    Not yet reported Dana-Farber Cancer Institute 21 participants Est. completion 2021-07-20 6 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03294694

    Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

    Not yet reported Dana-Farber Cancer Institute 33 participants Est. completion 2020-10-14 3 sites Stand-alone
    Other conditions: Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer, Metastatic Epithelial Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT03308201

    Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

    Not yet reported Tianjin Hemay Pharmaceutical Co., Ltd 55 participants Est. completion 2023-03-01 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03310541

    AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

    Not yet reported Memorial Sloan Kettering Cancer Center 12 participants Est. completion 2023-05-03 3 sites Stand-alone
    Other conditions: Breast Cancer, Prostate Cancer, Advanced Solid Tumors
    View official trial listing →
  • Completed NCT NCT03321981

    MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

    Not yet reported Merus B.V. 105 participants Est. completion 2023-07-26 25 sites
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Terminated NCT NCT03322215

    HR+/HER2- Advanced Breast Cancer and Endocrine Resistance

    Not yet reported Theodoros Foukakis 42 participants Est. completion 2023-10-31 9 sites Stand-alone
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Completed NCT NCT03324061

    Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration

    Not yet reported Eagle Pharmaceuticals, Inc. 600 participants Est. completion 2018-07-12 12 sites Stand-alone
    Other conditions: Pharmacokinetics
    View official trial listing →
  • Completed NCT NCT03344536

    A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 10 participants Est. completion 2021-08-12 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03355157

    A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

    Not yet reported GBG Forschungs GmbH 130 participants Est. completion 2024-08-30 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT03363893

    Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

    Not yet reported, Not yet reported Carrick Therapeutics Limited 124 participants Est. completion 2022-12-15 23 sites Stand-alone
    Other conditions: Advanced Solid Malignancies
    View official trial listing →
  • Withdrawn NCT NCT03377101

    Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

    Not yet reported National Cancer Institute (NCI) Est. completion 2018-08-07 Stand-alone
    Other conditions: Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Terminated NCT NCT03386162

    SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer

    Not yet reported UNICANCER 31 participants Est. completion 2022-11-18 14 sites Stand-alone
    Other conditions: Breast Cancer, PI3K, Alpelisib
    View official trial listing →
  • Active, not recruiting NCT NCT03393845

    Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

    Not yet reported Nancy Chan, MD 47 participants Est. completion 2027-09-01 5 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03425838

    Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

    Not yet reported Borstkanker Onderzoek Groep 1050 participants Est. completion 2028-12 72 sites
    Other conditions: Breast Neoplasm Female
    View official trial listing →
  • Terminated NCT NCT03439046

    Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

    Not yet reported Novartis Pharmaceuticals 287 participants Est. completion 2023-12-11 41 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03447132

    Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

    Not yet reported International Cancer Research Group, United Arab Emirates 354 participants Est. completion 2021-07-20 14 sites
    Other conditions: Breast Neoplasm Female
    View official trial listing →
  • Completed NCT NCT03462251

    Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

    Not yet reported iOMEDICO AG 41 participants Est. completion 2022-11-30 27 sites Stand-alone
    Other conditions: Breast Cancer, Hormone Receptor Positive Tumor, HER 2 Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT03481998

    A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

    Not yet reported, Not yet reported Jiangsu HengRui Medicine Co., Ltd. 104 participants Est. completion 2022-07-30 4 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT03507088

    Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer

    Not yet reported Zhimin Shao 36 participants Est. completion 2018-07-01 2 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03531645

    Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

    Not yet reported M.D. Anderson Cancer Center 18 participants Est. completion 2027-09-30 1 site Stand-alone
    Other conditions: Malignant Neoplasms of Female Genital Organs
    View official trial listing →
  • Completed NCT NCT03541863

    Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients

    Fudan University 131 participants Est. completion 2018-12-20 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03554044

    T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

    Not yet reported University of California, San Francisco 20 participants Est. completion 2023-12-31 1 site Stand-alone
    Other conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
    View official trial listing →
  • Completed NCT NCT03555877

    Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

    Not yet reported GBG Forschungs GmbH 56 participants Est. completion 2022-07-21 1 site Stand-alone
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Completed NCT NCT03575260

    500mg Fulvestrant Versus Exemestane in MBC

    Fudan University 120 participants Est. completion 2019-01-15 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03584009

    A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

    Not yet reported Hoffmann-La Roche 103 participants Est. completion 2021-05-06 40 sites Stand-alone
    Other conditions: Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT03620643

    Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

    Not yet reported Royal Marsden NHS Foundation Trust 33 participants Est. completion 2024-08-30 5 sites
    Other conditions: Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation
    View official trial listing →
  • Completed NCT NCT03633331

    Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

    Not yet reported Alliance for Clinical Trials in Oncology 93 participants Est. completion 2026-02-27 447 sites Stand-alone
    Other conditions: Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT03685331

    HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

    Not yet reported Abramson Cancer Center at Penn Medicine 9 participants Est. completion 2025-12-01 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
    View official trial listing →
  • Completed NCT NCT03691493

    Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

    Not yet reported Emory University 36 participants Est. completion 2022-10-13 10 sites Stand-alone
    Other conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Status unknown NCT NCT03750396

    Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

    Not yet reported Gangnam Severance Hospital 110 participants Est. completion 2025-07-31 1 site Stand-alone
    Other conditions: Breast Cancer, Recurrent Breast Cancer, Stereotactic Body Radiotherapy, Estrogen Receptor Positive Tumor, Her2-negative Tumor, Surgery
    View official trial listing →
  • Completed NCT NCT03767335

    MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

    Not yet reported Menarini Group 62 participants Est. completion 2024-02-23 27 sites Stand-alone
    Other conditions: Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03768479

    The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer

    Not yet reported First Affiliated Hospital Xi'an Jiaotong University 68 participants Est. completion 2019-03 1 site Stand-alone
    Other conditions: Estrogen Receptor-positive Breast Cancer, Fulvestrant
    View official trial listing →
  • Status unknown NCT NCT03772353

    Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

    Not yet reported, Not yet reported Fudan University 59 participants Est. completion 2025-12-10 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03778931

    Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

    Not yet reported Stemline Therapeutics, Inc. 478 participants Est. completion 2024-08-22 244 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03781063

    Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    Not yet reported Sermonix Pharmaceuticals Inc. 100 participants Est. completion 2025-05-08 51 sites
    Other conditions: Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT03803761

    A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

    Not yet reported, Not yet reported National Cancer Institute (NCI) Est. completion 2022-02-19 7 sites Stand-alone
    Other conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT03809988

    PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

    Not yet reported MedSIR 198 participants Est. completion 2022-11-30 53 sites Stand-alone
    Other conditions: Breast Cancer, Advanced Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    View official trial listing →
  • Completed NCT NCT03854903

    WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

    Not yet reported Georgetown University 19 participants Est. completion 2025-01-09 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03925233

    Breast Cancer Treatment Based on Organ-like Culture

    Xijing Hospital 300 participants Est. completion 2021-12-15 1 site
    Other conditions: Breast Cancer Organoids
    View official trial listing →
  • Completed NCT NCT03926936

    FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study

    Not yet reported Frederic Amant 17 participants Est. completion 2022-12-27 14 sites Stand-alone
    Obstructive sleep apnea Other conditions: Endometrial Stromal Sarcoma, Endometrial Cancer, Sex Cord Stromal Tumor, Serous Ovarian Tumor
    View official trial listing →
  • Status unknown NCT NCT03927456

    A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 357 participants Est. completion 2022-12-30 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03939897

    Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

    Not yet reported National Cancer Institute (NCI) 24 participants Est. completion 2027-07-31 14 sites Stand-alone
    Other conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Recurrent Breast Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT03959891

    AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

    Not yet reported Massachusetts General Hospital 77 participants Est. completion 2027-08 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04024436

    A Study of TAS-120 in Patients With Metastatic Breast Cancer

    Not yet reported Taiho Oncology, Inc. 64 participants Est. completion 2023-09-06 37 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
    View official trial listing →
  • Terminated NCT NCT04031885

    A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

    Not yet reported Eli Lilly and Company 4 participants Est. completion 2020-08-11 61 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04033172

    Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

    Not yet reported Chinese Academy of Medical Sciences 40 participants Est. completion 2021-09-01 1 site Stand-alone
    Other conditions: Breast Cancer, HER2-positive Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04034589

    Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 46 participants Est. completion 2022-07-06 2 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04053322

    Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

    Not yet reported UNICANCER 172 participants Est. completion 2027-08 2 sites Stand-alone
    Other conditions: ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
    View official trial listing →
  • Terminated NCT NCT04059484

    Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

    Not yet reported Sanofi 367 participants Est. completion 2025-01-02 109 sites
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Terminated NCT NCT04060862

    A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

    Not yet reported Hoffmann-La Roche 20 participants Est. completion 2023-08-29 20 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04092673

    Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

    Not yet reported, Not yet reported Effector Therapeutics 30 participants Est. completion 2025-03-31 14 sites Stand-alone
    Other conditions: Solid Tumor, Adult
    View official trial listing →
  • Active, not recruiting NCT NCT04115306

    Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

    Not yet reported, Not yet reported Phoenix Molecular Designs 61 participants Est. completion 2026-12 10 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04158362

    Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

    Not yet reported UNICANCER 180 participants Est. completion 2032-06 2 sites Stand-alone
    Other conditions: Cancer Metastatic
    View official trial listing →
  • Active, not recruiting NCT NCT04191499

    A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    Not yet reported, Not yet reported Hoffmann-La Roche 325 participants Est. completion 2027-11-15 135 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04214288

    A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

    Not yet reported AstraZeneca 240 participants Est. completion 2027-06-16 85 sites
    Other conditions: Advanced ER-Positive HER2-Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT04224272

    A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

    Not yet reported Jazz Pharmaceuticals 51 participants Est. completion 2025-06-30 13 sites Stand-alone
    Other conditions: HER2+/HR+ Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04227327

    Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

    Not yet reported University of Milano Bicocca 31 participants Est. completion 2024-07-25 39 sites
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT04247126

    A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

    Not yet reported Syros Pharmaceuticals 105 participants Est. completion 2023-03-30 16 sites Stand-alone
    Other conditions: Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
    View official trial listing →
  • Terminated NCT NCT04256941

    Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

    Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2023-09-22 1 site Stand-alone
    Other conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Status unknown NCT NCT04282031

    A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

    Not yet reported, Not yet reported Beta Pharma (Suzhou) Co., Ltd. 224 participants Est. completion 2025-06-30 1 site Stand-alone
    Other conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04289974

    Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

    Chinese Academy of Medical Sciences 100 participants Est. completion 2022-04 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04300790

    Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

    Not yet reported MedSIR 69 participants Est. completion 2025-03-16 19 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04305236

    Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

    Not yet reported University of California, Irvine 1 participants Est. completion 2022-02-16 1 site Stand-alone
    Other conditions: Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT04305496

    Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

    Not yet reported AstraZeneca 818 participants Est. completion 2026-06-22 215 sites Stand-alone
    Other conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT04316169

    Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

    Not yet reported Medical College of Wisconsin Est. completion 2028-01 1 site
    Other conditions: Solid Tumor, Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04318223

    Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

    Not yet reported Consorzio Oncotech 168 participants Est. completion 2023-07-31 19 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04334330

    Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

    Not yet reported Sun Yat-sen University 34 participants Est. completion 2024-12-31 2 sites Stand-alone
    Other conditions: Breast Cancer, Brain Metastases
    View official trial listing →
  • Status unknown NCT NCT04337658

    Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 493 participants Est. completion 2026-04-30 2 sites Stand-alone
    Other conditions: HER2-positive Breast Cancer
    View official trial listing →
  • Completed NCT NCT04352777

    Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

    Not yet reported Duke University 18 participants Est. completion 2025-06-25 1 site
    Other conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor
    View official trial listing →
  • Status unknown NCT NCT04355520

    A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

    Not yet reported, Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 42 participants Est. completion 2021-09 4 sites Stand-alone
    Other conditions: HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04355858

    Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

    Not yet reported Fudan University 319 participants Est. completion 2025-04-01 1 site Stand-alone
    Other conditions: Breast Cancer, Metastatic Cancer
    View official trial listing →
  • Completed NCT NCT04460911

    Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

    Pfizer 317 participants Est. completion 2022-04-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04483505

    Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.

    Not yet reported Fundacion CRIS de Investigación para Vencer el Cáncer 9 participants Est. completion 2023-04-04 8 sites Stand-alone
    Other conditions: Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast
    View official trial listing →
  • Completed NCT NCT04498481

    TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

    Pfizer 1 participants Est. completion 2018-07-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT04498520

    Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

    Not yet reported Pamela Munster Est. completion 2025-06-30 Stand-alone
    Other conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Endometrioid Adenocarcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Breast Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
    View official trial listing →
  • Status unknown NCT NCT04526028

    Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

    Tianjin Medical University Cancer Institute and Hospital 612 participants Est. completion 2023-05-31 1 site
    Other conditions: Breast Cancer, Fulvestrant, Palbociclib
    View official trial listing →
  • Active, not recruiting NCT NCT04539496

    A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

    Not yet reported, Not yet reported Sihuan Pharmaceutical Holdings Group Ltd. 402 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Metastasis Solid Tumors, Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04553133

    PF-07104091 as a Single Agent and in Combination Therapy

    Not yet reported Pfizer 157 participants Est. completion 2026-12-31 22 sites Stand-alone
    Other conditions: Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04557449

    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    Not yet reported Pfizer 362 participants Est. completion 2027-11-23 39 sites Stand-alone
    Obstructive sleep apnea Other conditions: Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
    View official trial listing →
  • Active, not recruiting NCT NCT04567420

    DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

    Not yet reported Criterium, Inc. 70 participants Est. completion 2028-12-31 19 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04572295

    A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

    Not yet reported Eisai Co., Ltd. 51 participants Est. completion 2026-06-18 11 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT04576455

    A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

    Not yet reported Hoffmann-La Roche 303 participants Est. completion 2027-08-25 81 sites
    Other conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04579380

    Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

    Not yet reported Seagen, a wholly owned subsidiary of Pfizer 217 participants Est. completion 2026-12-31 108 sites Stand-alone
    Other conditions: Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT04603183

    ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

    Not yet reported MedSIR 162 participants Est. completion 2025-06-30 31 sites Stand-alone
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Active, not recruiting NCT NCT04650581

    Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

    Not yet reported Canadian Cancer Trials Group 250 participants Est. completion 2026-12-31 39 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04657679

    Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

    Not yet reported Georgetown University 21 participants Est. completion 2023-10-30 3 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04707196

    A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

    Not yet reported Eli Lilly and Company 200 participants Est. completion 2023-01-09 15 sites Stand-alone
    Other conditions: Breast Neoplasms, Neoplasm Metastasis
    View official trial listing →
  • Terminated NCT NCT04726332

    Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

    Not yet reported Exelixis 52 participants Est. completion 2024-05-02 5 sites Stand-alone
    Other conditions: Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT04738292

    Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

    Not yet reported University of Wisconsin, Madison 11 participants Est. completion 2023-05-15 2 sites Stand-alone
    Other conditions: ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
    View official trial listing →
  • Status unknown NCT NCT04753177

    The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

    Not yet reported, Not yet reported Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary 120 participants Est. completion 2024-01-28 1 site Stand-alone
    Other conditions: The Neoadjuvant Therapy
    View official trial listing →
  • Active, not recruiting NCT NCT04762979

    Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

    Not yet reported Marina N Sharifi 44 participants Est. completion 2026-05 4 sites Stand-alone
    Other conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04778982

    Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd 4 participants Est. completion 2023-03-15 1 site
    Other conditions: HER2-positive Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04852081

    Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

    Blokhin's Russian Cancer Research Center 1000 participants Est. completion 2021-12-01 1 site
    Other conditions: Breast Cancer Stage IV
    View official trial listing →
  • Status unknown NCT NCT04856371

    Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

    Not yet reported Haihe Biopharma Co., Ltd. 228 participants Est. completion 2022-12 Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04862143

    Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

    Not yet reported Novartis Pharmaceuticals 2 participants Est. completion 2022-09-19 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04862663

    Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

    Not yet reported AstraZeneca 893 participants Est. completion 2029-08-14 225 sites Stand-alone
    Other conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04899349

    Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

    Not yet reported Novartis Pharmaceuticals 2 participants Est. completion 2023-05-10 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT04901299

    Fulvestrant + Neratinib In Breast Cancer

    Not yet reported Massachusetts General Hospital Est. completion 2025-07-01 2 sites Stand-alone
    Other conditions: Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
    View official trial listing →
  • Completed NCT NCT04916509

    Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

    Pfizer 258 participants Est. completion 2022-12-27 7 sites
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT04920708

    Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

    Not yet reported Royal Marsden NHS Foundation Trust 57 participants Est. completion 2027-06 13 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04936295

    Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

    Not yet reported Sun Yat-sen University 61 participants Est. completion 2025-06-01 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04967248

    A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

    Novartis Pharmaceuticals 4 participants Est. completion 2024-10-18
    Other conditions: Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
    View official trial listing →
  • Active, not recruiting NCT NCT04975308

    A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

    Not yet reported Eli Lilly and Company 874 participants Est. completion 2027-08 243 sites Stand-alone
    Other conditions: Breast Neoplasms, Neoplasm Metastasis
    View official trial listing →
  • Status unknown NCT NCT04999540

    Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer

    Not yet reported Guangdong Women and Children Hospital 73 participants Est. completion 2024-12-30 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05000736

    Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC

    Chinese Academy of Medical Sciences 600 participants Est. completion 2022-09-01 1 site
    Other conditions: Hormone Receptor Positive Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT05022342

    Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world

    Novartis Pharmaceuticals 595 participants Est. completion 2025-02-11 28 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05038735

    Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

    Not yet reported Novartis Pharmaceuticals 210 participants Est. completion 2027-02-26 68 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05041842

    Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

    Not yet reported UNICANCER 53 participants Est. completion 2026-04-30 16 sites Stand-alone
    Other conditions: Metastatic Breast Cancer With a Isolated Brain Progression
    View official trial listing →
  • Status unknown NCT NCT05047848

    Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer

    Not yet reported Liaoning Cancer Hospital & Institute 82 participants Est. completion 2023-09-18 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT05054374

    A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 6 participants Est. completion 2023-10-26 4 sites Stand-alone
    Other conditions: Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma, MEK1 Gene Mutation, MEK2 Gene Mutation, Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT05054751

    GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

    Not yet reported Genor Biopharma Co., Ltd. 275 participants Est. completion 2024-03-30 54 sites Stand-alone
    Other conditions: Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05063786

    Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

    Not yet reported Spanish Breast Cancer Research Group 27 participants Est. completion 2026-06 106 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Terminated NCT NCT05065411

    Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

    Not yet reported Veru Inc. 5 participants Est. completion 2024-01-09 30 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05075512

    The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

    Not yet reported Zhejiang Cancer Hospital 40 participants Est. completion 2026-08-31 1 site Stand-alone
    Other conditions: Breast Neoplasm Female
    View official trial listing →
  • Status unknown NCT NCT05076695

    Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

    Not yet reported Fudan University 37 participants Est. completion 2024-10-15 1 site Stand-alone
    Other conditions: Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05077449

    A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

    Not yet reported Xuanzhu Biopharmaceutical Co., Ltd. 300 participants Est. completion 2029-11 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT05079360

    Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

    Not yet reported Veru Inc. Est. completion 2024-05-26 26 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT05085002

    A Study of Lerociclib in Participants With Advanced Breast Cancer

    Not yet reported EQRx, Inc. 100 participants Est. completion 2023-11-29 21 sites
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05135104

    Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period

    Asociatia Oncohelp - Centrul de Oncologie Oncohelp 650 participants Est. completion 2024-05-25 7 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05140655

    Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-

    Dr. Reddy's Laboratories SAS 40 participants Est. completion 2022-08-19 1 site
    Other conditions: Breast Neoplasm Female
    View official trial listing →
  • Active, not recruiting NCT NCT05154487

    A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

    Not yet reported GOG Foundation 51 participants Est. completion 2028-11-01 21 sites Stand-alone
    Other conditions: Endometroid Endometrial Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05161195

    Roll-over Study to Allow Continued Access to Ribociclib

    Not yet reported Novartis Pharmaceuticals 134 participants Est. completion 2030-08-14 73 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05169567

    Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

    Not yet reported Eli Lilly and Company 368 participants Est. completion 2027-12 138 sites Stand-alone
    Other conditions: Breast Neoplasm, Neoplasm Metastasis
    View official trial listing →
  • Terminated NCT NCT05176080

    Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

    Not yet reported, Not yet reported Henan Cancer Hospital 46 participants Est. completion 2024-07-03 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05186545

    An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

    Not yet reported The First Affiliated Hospital of Zhengzhou University 63 participants Est. completion 2025-07 5 sites Stand-alone
    Other conditions: Breast Cancer, Breast Cancer Female
    View official trial listing →
  • Withdrawn NCT NCT05191004

    Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

    Not yet reported, Not yet reported Nuvation Bio Inc. Est. completion 2026-09 5 sites Stand-alone
    Other conditions: Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor
    View official trial listing →
  • Status unknown NCT NCT05191914

    Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors

    Not yet reported Liaoning Cancer Hospital & Institute 20 participants Est. completion 2022-12-30 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05205200

    Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

    Not yet reported Fudan University 338 participants Est. completion 2026-08-01 1 site Stand-alone
    Other conditions: Breast Cancer, Metastatic Cancer
    View official trial listing →
  • Terminated NCT NCT05207709

    Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

    Not yet reported SOLTI Breast Cancer Research Group 61 participants Est. completion 2026-03-26 71 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05230810

    Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

    Not yet reported, Not yet reported Criterium, Inc. 40 participants Est. completion 2026-06-30 4 sites Stand-alone
    Other conditions: HER2-positive Metastatic Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT05238831

    SMMART Adaptive Clinical Treatment (ACT) Trial

    Not yet reported OHSU Knight Cancer Institute Est. completion 2026-05-31 Stand-alone
    Other conditions: Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT05238922

    Study of INCB123667 in Subjects With Advanced Solid Tumors

    Not yet reported Incyte Corporation 291 participants Est. completion 2027-08-31 41 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Active, not recruiting NCT NCT05251714

    CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

    Not yet reported, Not yet reported Treadwell Therapeutics, Inc 44 participants Est. completion 2026-08 4 sites Stand-alone
    Other conditions: Advanced Solid Tumor, Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05262400

    A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

    Not yet reported, Not yet reported Pfizer 235 participants Est. completion 2027-02-26 44 sites Stand-alone
    Other conditions: Breast Cancer, Solid Tumors
    View official trial listing →
  • Active, not recruiting NCT NCT05306340

    A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

    Not yet reported Genentech, Inc. 373 participants Est. completion 2026-10-15 136 sites
    Other conditions: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05319873

    Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

    Not yet reported, Not yet reported Jonsson Comprehensive Cancer Center 18 participants Est. completion 2028-04-01 1 site Stand-alone
    Other conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Positive Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Status unknown NCT NCT05328440

    Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

    Not yet reported Henan Cancer Hospital 120 participants Est. completion 2026-01-01 1 site Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Status unknown NCT NCT05343117

    Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

    Chinese Academy of Medical Sciences 400 participants Est. completion 2024-06-01 9 sites
    Other conditions: Hormone Receptor Positive Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05365178

    To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

    Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 432 participants Est. completion 2026-06 88 sites Stand-alone
    Other conditions: HR-positive, HER2-negative Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT05375461

    TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

    Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 293 participants Est. completion 2025-12-09 2 sites Stand-alone
    Other conditions: HR-positive,HER2-negative in Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05411380

    Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

    Not yet reported wang shusen 73 participants Est. completion 2025-04-01 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT05427617

    Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer

    Hunan Cancer Hospital 223 participants Est. completion 2021-06-30
    Other conditions: Metastatic Breast Cancer, Circulating Tumor DNA, Gene Abnormality
    View official trial listing →
  • Status unknown NCT NCT05433480

    A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

    Not yet reported Betta Pharmaceuticals Co., Ltd. 274 participants Est. completion 2025-07-31 64 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05438810

    This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

    Not yet reported Ahon Pharmaceutical Co., Ltd. 312 participants Est. completion 2024-05-18 1 site Stand-alone
    Other conditions: Advanced Breast Cancer, Female Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05463601

    Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 132 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05501886

    Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

    Not yet reported Celcuity Inc 701 participants Est. completion 2026-12-31 235 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05504213

    A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 224 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05546268

    Study of Oral MRT-2359 in Selected Cancer Patients

    Not yet reported, Not yet reported Monte Rosa Therapeutics, Inc 174 participants Est. completion 2027-11 17 sites Stand-alone
    Other conditions: NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
    View official trial listing →
  • Status unknown NCT NCT05574881

    Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

    Not yet reported, Not yet reported Fudan University 72 participants Est. completion 2025-01-01 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT05584644

    A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

    Pfizer 150 participants Est. completion 2022-02-22 6 sites
    Other conditions: Breast Cancer, Breast Carcinoma, Breast Neoplasms, Breast Tumors, Cancer of Breast
    View official trial listing →
  • Completed NCT NCT05631795

    Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

    Not yet reported Novartis Pharmaceuticals 40 participants Est. completion 2025-06-12 12 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05654623

    A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

    Not yet reported Pfizer 624 participants Est. completion 2028-05-15 312 sites
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05670054

    Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients

    Not yet reported Mansoura University 116 participants Est. completion 2023-12-15 1 site
    Other conditions: Breast Cancer Stage IV
    View official trial listing →
  • Status unknown NCT NCT05680194

    Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients

    Peking Union Medical College Hospital 1000 participants Est. completion 2025-12-01 1 site
    Other conditions: Breast Cancer Female
    View official trial listing →
  • Active, not recruiting NCT NCT05759572

    Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

    Not yet reported Fudan University 145 participants Est. completion 2027-07-01 1 site Stand-alone
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Completed NCT NCT05759949

    First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

    Not yet reported Relay Therapeutics, Inc. 41 participants Est. completion 2025-04-11 7 sites Stand-alone
    Other conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
    View official trial listing →
  • Completed NCT NCT05789771

    Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.

    Blokhin's Russian Cancer Research Center 136 participants Est. completion 2022-12-01 1 site
    Other conditions: HR+/HER2- Breast Cancer, Metastatic Disease, Аdvanced Disease
    View official trial listing →
  • Status unknown NCT NCT05792410

    A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

    Not yet reported, Not yet reported Jiangsu HengRui Medicine Co., Ltd. 300 participants Est. completion 2025-02-27 Stand-alone
    Other conditions: HER2 Low Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05806047

    Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy

    Not yet reported Fudan University 23 participants Est. completion 2024-11-01 Stand-alone
    Other conditions: Hormone Receptor-positive Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05808582

    Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 60 participants Est. completion 2024-09-01 Stand-alone
    Other conditions: Hormone Receptor-positive Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05826964

    Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

    Not yet reported University of Miami 24 participants Est. completion 2029-07-31 1 site Stand-alone
    Other conditions: Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05861830

    Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)

    Not yet reported Peking Union Medical College Hospital 80 participants Est. completion 2026-06-30 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05870579

    [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

    Not yet reported Novartis Pharmaceuticals 28 participants Est. completion 2032-05-27 13 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT05905341

    Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

    Not yet reported Pfizer Est. completion 2028-04-13 Stand-alone
    Obstructive sleep apnea Other conditions: Breast Cancer, Ovarian Cancer, Non-small Cell Lung Cancer (NSCLC), Endometrial, Solid Tumors
    View official trial listing →
  • Terminated NCT NCT05932667

    Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

    Not yet reported Institut Curie 1 participants Est. completion 2023-11-30 6 sites Stand-alone
    Other conditions: Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT05963984

    A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

    Not yet reported Carrick Therapeutics Limited 60 participants Est. completion 2025-08-28 32 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06016738

    OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

    Not yet reported Olema Pharmaceuticals, Inc. 510 participants Est. completion 2028-02-29 233 sites
    Other conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT06027541

    Young Patients With Early Breast Cancer

    Peking Union Medical College Hospital 1000 participants Est. completion 2028-02-01 1 site
    Other conditions: Breast Cancer Female
    View official trial listing →
  • Completed NCT NCT06047184

    Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

    Not yet reported BeBetter Med Inc 100 participants Est. completion 2024-01-30 2 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06065748

    A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

    Not yet reported Hoffmann-La Roche 1050 participants Est. completion 2029-02-12 311 sites
    Other conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT06074757

    Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study

    Not yet reported Kashiv BioSciences, LLC 48 participants Est. completion 2023-10-01 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06105632

    A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

    Not yet reported Pfizer 333 participants Est. completion 2028-01-21 48 sites Stand-alone
    Other conditions: Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT06133088

    Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

    Not yet reported Zhejiang Cancer Hospital 53 participants Est. completion 2025-08-31 1 site
    Other conditions: Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
    View official trial listing →
  • Status unknown NCT NCT06172322

    A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

    Not yet reported Nanjing Chia-tai Tianqing Pharmaceutical 42 participants Est. completion 2025-07 1 site Stand-alone
    Other conditions: HR Positive/HER-2 Negative Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06239467

    First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

    Not yet reported OnKure, Inc. 200 participants Est. completion 2027-08-01 33 sites Stand-alone
    Other conditions: Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
    View official trial listing →
  • Completed NCT NCT06253195

    BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

    Not yet reported BeOne Medicines 33 participants Est. completion 2026-04-23 7 sites Stand-alone
    Other conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Hormone-receptor-positive Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06257264

    A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

    Not yet reported BeiGene 103 participants Est. completion 2026-08-31 24 sites Stand-alone
    Other conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
    View official trial listing →
  • Completed NCT NCT06311383

    A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

    Novartis Pharmaceuticals 2610 participants Est. completion 2025-03-10 265 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT06339281

    A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

    Not yet reported Li Huiping 68 participants Est. completion 2026-12
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT06341283

    A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer

    The Affiliated Hospital of Qingdao University 200 participants Est. completion 2025-07-01 1 site
    Other conditions: Breast Cancer, Neoplasms, Breast Diseases
    View official trial listing →
  • Completed NCT NCT06375707

    First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 74 participants Est. completion 2026-05-30 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Terminated NCT NCT06408168

    Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

    Not yet reported M.D. Anderson Cancer Center 6 participants Est. completion 2025-12-08 1 site Stand-alone
    Other conditions: Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT06428396

    Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

    Not yet reported Merck Sharp & Dohme LLC 120 participants Est. completion 2028-12-25 41 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Enrolling by invitation NCT NCT06481956

    T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

    Not yet reported Zheng Yabing 40 participants Est. completion 2027-10-10 1 site Stand-alone
    Other conditions: HER2-positive Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06494150

    Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

    Not yet reported University of Oklahoma 37 participants Est. completion 2029-09 1 site Stand-alone
    Other conditions: Low Grade Ovarian Serous Adenocarcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT06506955

    Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

    Not yet reported, Not yet reported Taiho Oncology, Inc. 15 participants Est. completion 2027-04-30 9 sites Stand-alone
    Other conditions: Advanced/Metastatic Cancer
    View official trial listing →
  • Completed NCT NCT06525675

    Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

    MedSIR 419 participants Est. completion 2024-09-02 36 sites
    Other conditions: Metastatic Breast Cancer, Advanced Breast Cancer, Luminal Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT06561022

    Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping

    Not yet reported Fudan University 260 participants Est. completion 2026-06-30 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT06585969

    A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

    Not yet reported Danish Breast Cancer Cooperative Group Est. completion 2026-01-01
    Other conditions: Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B, Her2 Enriched, Basal Like
    View official trial listing →
  • Active, not recruiting NCT NCT06590857

    Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

    Not yet reported, Not yet reported RayzeBio, Inc. 16 participants Est. completion 2033-11 31 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer With Bone Involvement, Bone Metastases in Subjects With Advanced Breast Cancer, ER-Positive HER2-Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Hormone-sensitive Metastatic Breast Cancer, Hormone-Sensitive Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06635447

    Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

    Not yet reported AstraZeneca 293 participants Est. completion 2027-01-10 76 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06680921

    A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

    Not yet reported Jiangsu Simcere Pharmaceutical Co., Ltd. 482 participants Est. completion 2028-08-31 57 sites
    Other conditions: Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06702618

    Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

    Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 33 participants Est. completion 2026-12 13 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT06750848

    Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer

    Not yet reported Jundong Wu 48 participants Est. completion 2026-07-01 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06764186

    A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

    Not yet reported AstraZeneca 101 participants Est. completion 2027-12-31 17 sites Stand-alone
    Other conditions: Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT06849947

    Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

    Not yet reported Yeon Hee Park 272 participants Est. completion 2031-12-31 Stand-alone
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Terminated NCT NCT06851442

    Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

    Not yet reported, Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 8 participants Est. completion 2025-11-20 17 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT06929325

    Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 312 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: HR+/HER2- Advanced/Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06957379

    Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 78 participants Est. completion 2025-12 1 site Stand-alone
    Other conditions: HR+/HER2- Advanced/Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT07008963

    Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

    AstraZeneca 48 participants Est. completion 2025-11-28 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT07038369

    A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

    Not yet reported Atavistik Bio, Inc 134 participants Est. completion 2029-01-31 8 sites Stand-alone
    Other conditions: Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms, ER Positive Breast Cancer, Cervical Cancers, Cervical Neoplasms, Cervical Carcinoma, Triple Negative Breast Cancer, Gynecologic Cancers, Gynecologic Neoplasm, Endometrial Cancer, Endometrial Neoplasm, Endometrial Carcinoma (EC), Fallopian Cancer, Ovarian Carcinoma, Ovarian Cancer, Ovarian Neoplasms, Prostate Cancers, Prostate Carcinoma, Solid Tumors, Neoplasms, Neoplasms by Site, Breast Diseases, Uterine Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms
    View official trial listing →
  • Not yet recruiting NCT NCT07179939

    Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

    Not yet reported Fudan University 288 participants Est. completion 2031-12-30 1 site Stand-alone
    Other conditions: HER2-positive Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07235618

    A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

    Not yet reported Sun Yat-sen University 50 participants Est. completion 2028-12-30 1 site Stand-alone
    Other conditions: Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07333937

    Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer

    Not yet reported Xijing Hospital 35 participants Est. completion 2028-11-20 Stand-alone
    Other conditions: Brest Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07340619

    Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

    Not yet reported UNICANCER 51 participants Est. completion 2029-11-18 8 sites Stand-alone
    Other conditions: Metastatic (Stage IV) Melanoma
    View official trial listing →
  • Not yet recruiting NCT NCT07366632

    A Study of Single Dose of BL0175 in Postmenopausal Women

    Not yet reported Shanghai Best-Link Bioscience, LLC 27 participants Est. completion 2026-12-21 Stand-alone
    Other conditions: Postmenopausal Women
    View official trial listing →
  • Not yet recruiting NCT NCT07393321

    A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

    Not yet reported Nanjing Chia-tai Tianqing Pharmaceutical 210 participants Est. completion 2031-08-31 Stand-alone
    Other conditions: HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT07408089

    Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

    Not yet reported Boundless Bio, Inc. 8 participants Est. completion 2026-07-28 8 sites Stand-alone
    Other conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07480681

    Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor

    Not yet reported Shanghai Henlius Biotech 138 participants Est. completion 2028-06 Stand-alone
    Other conditions: Advanced/Metastatic Solid Tumors
    View official trial listing →
  • Active, not recruiting NCT NCT07557004

    A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.

    Not yet reported Nanjing Sanhome Pharmaceutical, Co., Ltd. 30 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: HR+ / HER2- Advanced Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT07570966

    Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

    Not yet reported, Not yet reported Novartis Pharmaceuticals Est. completion 2031-08-01 Stand-alone
    Other conditions: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer (mCRPC)
    View official trial listing →
  • Not yet recruiting NCT NCT07618390

    A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 160 participants Est. completion 2028-12 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07619066

    A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.

    Not yet reported MedSIR 25 participants Est. completion 2028-11-28 Stand-alone
    Other conditions: Advanced Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer, HER2 Mutation
    View official trial listing →
  • Not yet recruiting NCT NCT07679269

    Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.

    Not yet reported Novartis Pharmaceuticals 51 participants Est. completion 2031-07-25
    Other conditions: PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
    View official trial listing →
  • Not yet recruiting NCT NCT07683754

    T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

    Not yet reported Daiichi Sankyo 200 participants Est. completion 2030-08-28 Stand-alone
    Other conditions: Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
    View official trial listing →
  • Not yet recruiting NCT NCT07716046

    Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer

    Not yet reported Fudan University 240 participants Est. completion 2032-12-31 Stand-alone
    Other conditions: Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer, HR+/HER2+ Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07729046

    Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

    Not yet reported University of California, San Diego 150 participants Est. completion 2035-06 1 site
    Other conditions: Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07748208

    A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

    Not yet reported Hoffmann-La Roche 40 participants Est. completion 2029-09-30 Stand-alone
    Other conditions: Breast Cancer, Diabetes Type II
    View official trial listing →
  • Not yet recruiting NCT NCT07767474

    A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

    Not yet reported, Not yet reported Antares Therapeutics, Inc 343 participants Est. completion 2030-01-31 Stand-alone
    Other conditions: Advanced Solid Tumors
    View official trial listing →
  • Not yet recruiting NCT NCT07784036

    JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer

    Not yet reported Chengdu JOYO pharma Co., Ltd. 171 participants Est. completion 2029-06-30 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07787520

    A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors

    Not yet reported Laekna Limited 150 participants Est. completion 2029-12 6 sites Stand-alone
    Other conditions: Patients With Advanced Solid Tumors
    View official trial listing →
  • Not yet recruiting NCT NCT07802626

    Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing

    Not yet reported SWOG Cancer Research Network 1084 participants Est. completion 2035-10-30 Stand-alone
    Other conditions: HR Positive/HER-2 Negative Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07811232

    A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers

    Not yet reported, Not yet reported Advenchen Pharmaceuticals, LLC. 138 participants Est. completion 2031-09-01 1 site Stand-alone
    Other conditions: Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.